Target intelligence / Profile preview

Inflamed immune microenvironment (IME)

Target
IME
Molecular classification
Other
01

Overview

The inflamed immune microenvironment is a complex biological state characterized by the dense infiltration of activated immune cells, such as T lymphocytes, macrophages, and dendritic cells, within a specific tissue or tumor site (Binnewies et al., 2018, Nature Medicine). This environment is defined by high levels of pro-inflammatory mediators, including cytokines like interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and various chemokines that facilitate ongoing immune recruitment and activation (Chen & Mellman, 2017, Nature). In oncology, an 'inflamed' or 'hot' tumor microenvironment is often associated with a more robust response to immunotherapies, as the pre-existing immune infiltrate can be effectively re-activated to target malignant cells (Gajewski et al., 2013, Current Opinion in Immunology). Conversely, in the context of autoimmune and chronic inflammatory diseases, this microenvironment represents a pathological state where dysregulated immune activity leads to persistent tissue damage and organ dysfunction (Medzhitov, 2008, Nature). Because it describes a multi-component cellular ecosystem rather than a single molecular entity, it is considered a physiological phenotype or milieu rather than a discrete therapeutic target.

Other names
Inflamed tumor microenvironmentHot tumorPro-inflammatory microenvironmentImmune-inflamed phenotypeT-cell inflamed tumor microenvironment
02

Mechanism of action

Therapeutic strategies involve modulating the cellular and cytokine composition of the milieu, such as through immune checkpoint inhibition to enhance anti-tumor activity or cytokine neutralization to resolve pathological inflammation (Chen & Mellman, 2017, Nature).

03

Biological functions

Immune responseInflammationCell-cell communicationSignal transductionLeukocyte chemotaxis
04

Disease associations

CancerAutoimmune diseaseChronic inflammationInfectionFibrosis
05

Safety considerations

Cytokine release syndrome (CRS)Immune-related adverse events (irAEs)Systemic autoimmunityTissue damage and fibrosis
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Tumor-infiltrating lymphocytes (TILs)Interferon-gamma (IFN-γ) gene expression signatureProgrammed death-ligand 1 (PD-L1) expressionC-reactive protein (CRP)Pro-inflammatory cytokine levels (e.g., IL-6, TNF-α)

Beyond the preview

Go deeper on Inflamed immune microenvironment (IME).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inflamed immune microenvironment (IME).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call